ClinicalTrials.gg

Program

Cholestyramine Resin

Also written as “Cholestyramine”, “cholestyramine” and “A3384”.

Its studies are mostly in Multiple Sclerosis · Hypercholesterolemia · Liver Cirrhosis, Biliary · Short Bowel Syndrome, led by 4 companies.

Furthest: phase 3, since May 23, 201310 company-led studies, 1 open or runningNext primary completion: May 16, 2031 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi61 open or runningphase 3since May 23, 2013May 23, 2013May 16, 2031phase 3 · NCT07930624
Ipsen20 open or runningphase 2since Mar 3, 2014Mar 3, 2014none ahead
Eli Lilly10 open or runningphase 1since Jun 6, 2023Jun 6, 2023none ahead
Pharmascience10 open or runningphase 2since Jul 26, 2019Jul 26, 2019none ahead

Also a collaborator on its studies: Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 23, 2013First study: phase 3 study in Multiple SclerosisNew to SanofiSanofi · NCT01863888 · 70 enrolled · Belgium, Germany, Netherlands
  2. Jan 23, 2014Phase 1 study in Multiple SclerosisSanofi · NCT02046629 · 12 enrolled · China
  3. Mar 3, 2014Ipsen's first study: phase 2 study in Bile Acid MalabsorptionNew to IpsenIpsen · NCT02078856 · 19 enrolled · Sweden, United Kingdom
  4. Aug 31, 2016Phase 2 study in HypercholesterolemiaSanofi · NCT02890992 · 42 enrolled · United States, Canada, Czechia and more
  5. Nov 1, 2016Phase 1 study in Liver Cirrhosis, BiliaryIpsen · NCT02963077 · 94 enrolled
  6. Apr 18, 20182 phase 3 studies in HypercholesterolemiaSanofi · NCT03510884, NCT03510715
  7. Jul 26, 2019Pharmascience's first study: phase 2 study in Short Bowel SyndromeNew to PharmasciencePharmascience · NCT04046328 · 13 enrolled · Poland
  8. Jun 6, 2023Eli Lilly's first study: phase 1 study in HealthyNew to Eli LillyEli Lilly · NCT05894928 · 21 enrolled · United States
  9. Nov 3, 2026Phase 3 study in Multiple SclerosisSanofi · NCT07930624 · 2,500 planned

Ahead

  1. May 16, 2031Primary completion: phase 3 study in Multiple SclerosisSanofi · NCT07930624

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07930624Multiple Sclerosis3Not yet recruitingSanofiMay 16, 20312,500
NCT05894928Healthy · United States1CompletedEli LillyJul 9, 202321
NCT04046328Short Bowel Syndrome · Poland2TerminatedPharmascienceDec 22, 202113
NCT03510884Hypercholesterolemia · United States, Argentina, Austria and more3CompletedSanofiJan 14, 2021153
NCT03510715Hypercholesterolemia · Brazil, Canada, Denmark and more3CompletedSanofiFeb 17, 202018
NCT02963077Liver Cirrhosis, Biliary1CompletedIpsenMay 201494
NCT02890992Hypercholesterolemia · United States, Canada, Czechia and more2CompletedSanofiSep 13, 201842
NCT02078856Bile Acid Malabsorption · Sweden, United Kingdom2CompletedIpsenDec 201419
NCT02046629Multiple Sclerosis · China1CompletedSanofiJul 201412
NCT01863888Multiple Sclerosis · Belgium, Germany, Netherlands3CompletedSanofiJan 201570

How it is read

Names in the registry

  • “Cholestyramine”, 4 entries
  • “cholestyramine”, 3 entries
  • “A3384”, 1 entry
  • “CRC (A3384)”, 1 entry
  • “Questran”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.